Overview
Italy-based drug containment firm's Q4 revenue rose 5%, beating analyst expectations
Adjusted diluted EPS for Q4 was €0.18
Company expects fiscal 2026 revenue between €1.26 bln and €1.29 bln
Outlook
Stevanato expects 2026 revenue between €1.26 bln and €1.29 bln
Company forecasts 2026 adjusted EBITDA of €331.8 mln to €346.9 mln
Stevanato anticipates 2026 adjusted EPS between €0.59 and €0.63
Result Drivers
BDS SEGMENT GROWTH - Revenue from Biopharmaceutical and Diagnostic Solutions segment grew 10%, driven by high-value solutions
HIGH-VALUE SOLUTIONS - Revenue from high-value solutions increased 31%, representing 49% of total revenue
ENGINEERING SEGMENT DECLINE - Engineering Segment revenue decreased 23% due to lower demand in glass converting and assembly lines
Company press release: ID:nBw62FM98a
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Beat | EUR 346.50 mln | EUR 333.01 mln (9 Analysts) |
Q4 EPS | EUR 0.17 | ||
Q4 Net Income | EUR 47.60 mln | ||
Q4 Gross Profit | EUR 106.90 mln | ||
Q4 Operating Income | EUR 70.10 mln | ||
Q4 Pretax Profit | EUR 65.80 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Stevanato Group SpA is $28.00, about 90.1% above its March 3 closing price of $14.73
The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 32 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)